HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Penhaligon’s boutiques in Saks

This article was originally published in The Rose Sheet

Executive Summary

Penhaligon's parent company Cradle Holdings enters agreement with Saks Fifth Avenue to open six Penhaligon's outposts within Saks stores in the fall, retailer announces. Saks will open additional Penhaligon's boutiques over next several years, and will be exclusive point of distribution for specialty beauty brand outside of free-standing Penhaligon's stores. Cradle Holdings acquired Penhaligon's and Erno Laszlo in February (1"The Rose Sheet" Feb. 18, 2002, p. 7)...

You may also be interested in...

Penhaligon’s Owner Cradle Holdings Initiates U.S. Expansion

The specialty UK beauty brand Penhaligon's will undergo its first major U.S. expansion under Cradle Holdings, a new cosmetics business entity formed by private equity firm Fox Paine to "acquire and nurture promising prestige beauty companies.

Hikma And Civica Ship Eight Essential Injectables

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

AstraZeneca's Calquence Steps Up in First-Line CLL

A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts